TRCT
ATNM icon

Tower Research Capital (TRC)’s Actinium Pharmaceuticals ATNM Stock Holding History

Tower Research Capital (TRC)’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-555
Closed -$888 – 5137
2025
Q3 		$888 Sell
555
-1,923
-78% -$3.13K ﹤0.01% 4914
2025
Q2 		$3.47K Sell
2,478
-5,871
-70% -$8.79K ﹤0.01% 4491
2025
Q1 		$13.4K Sell
8,349
-1,198
-13% -$1.52K ﹤0.01% 3365
2024
Q4 		$12K Buy
9,547
+5,569
+140% +$8.64K ﹤0.01% 3661
2024
Q3 		$7.48K Sell
3,978
-1,285
-24% -$5.08K ﹤0.01% 4047
2024
Q2 		$38.9K Buy
5,263
+2,915
+124% +$24K ﹤0.01% 3288
2024
Q1 		$18.4K Buy
2,348
+250
+12% +$1.61K ﹤0.01% 3074
2023
Q4 		$10.7K Sell
2,098
-284
-12% -$1.46K ﹤0.01% 4218
2023
Q3 		$14.1K Buy
2,382
+1,403
+143% +$9.34K ﹤0.01% 3711
2023
Q2 		$7.26K Buy
979
+643
+191% +$5.47K ﹤0.01% 4595
2023
Q1 		$3K Sell
336
-100
-23% -$1.06K ﹤0.01% 5169
2022
Q4 		$5K Sell
436
-4,129
-90% -$41.9K ﹤0.01% 4834
2022
Q3 		$33K Sell
4,565
-1,241
-21% -$7.71K ﹤0.01% 3514
2022
Q2 		$28K Buy
5,806
+4,771
+461% +$27.1K ﹤0.01% 3431
2022
Q1 		$6K Buy
1,035
+133
+15% +$700 ﹤0.01% 4848
2021
Q4 		$5K Buy
902
+702
+351% +$5.27K ﹤0.01% 5128
2021
Q3 		$2K Sell
200
-3,608
-95% -$25.1K ﹤0.01% 5231
2021
Q2 		$30K Buy
3,808
+1,897
+99% +$14.9K ﹤0.01% 3476
2021
Q1 		$15K Buy
+1,911
New +$16.2K ﹤0.01% 4091
2020
Q4 		– Sell
-1,481
Closed -$14K – 5116
2020
Q3 		$14K Buy
1,481
+321
+28% +$3.54K ﹤0.01% 3955
2020
Q2 		$12K Buy
+1,160
New +$8.79K ﹤0.01% 3919
2015
Q4 		– Sell
-247
Closed -$13K – 4453
2015
Q3 		$13K Sell
247
-327
-57% -$21.8K ﹤0.01% 2081
2015
Q2 		$45K Buy
574
+551
+2,396% +$47K ﹤0.01% 1447
2015
Q1 		$2K Sell
23
-298
-93% -$35.4K ﹤0.01% 3721
2014
Q4 		$57K Buy
321
+65
+25% +$12.3K 0.01% 954
2014
Q3 		$51K Buy
256
+218
+574% +$43.2K 0.01% 1512
2014
Q2 		$8K Buy
+38
New +$12.7K ﹤0.01% 2501

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tower Research Capital (TRC)'s ATNM Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of Actinium Pharmaceuticals (ATNM) in Q4 2025, closing a stake of 555 shares — an estimated $888 sold.

Tower Research Capital (TRC) first reported a position in ATNM in Q2 2014 and held it in 27 quarters. The position peaked at $57K in Q4 2014. 60 funds tracked by Wall St. Rank hold ATNM as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining Actinium Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 555 Actinium Pharmaceuticals shares in Q4 2025, an estimated $888.
  • Tower Research Capital (TRC) first reported a position in Actinium Pharmaceuticals in Q2 2014 and held it in 27 quarters.
  • Tower Research Capital (TRC)'s Actinium Pharmaceuticals position peaked at $57K in Q4 2014.
  • 60 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.